Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far
- PMID: 35354477
- PMCID: PMC8969238
- DOI: 10.1186/s12929-022-00806-1
Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far
Abstract
Bacteriophages (phages) may be used as an alternative to antibiotic therapy for combating infections caused by multidrug-resistant bacteria. In the last decades, there have been studies concerning the use of phages and antibiotics separately or in combination both in animal models as well as in humans. The phenomenon of phage-antibiotic synergy, in which antibiotics may induce the production of phages by bacterial hosts has been observed. The potential mechanisms of phage and antibiotic synergy was presented in this paper. Studies of a biofilm model showed that a combination of phages with antibiotics may increase removal of bacteria and sequential treatment, consisting of phage administration followed by an antibiotic, was most effective in eliminating biofilms. In vivo studies predominantly show the phenomenon of phage and antibiotic synergy. A few studies also describe antagonism or indifference between phages and antibiotics. Recent papers regarding the application of phages and antibiotics in patients with severe bacterial infections show the effectiveness of simultaneous treatment with both antimicrobials on the clinical outcome.
Keywords: Animal model; Antibiotic; Bacteriophage; Human phage therapy; Phage–antibiotic synergy.
© 2022. The Author(s).
Conflict of interest statement
AG, BWD and RM are co-inventors for patents covering preparation and application of therapeutic phages owned by the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland. Other authors declare that they have no conflict of interest.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
